Literature DB >> 31267501

Vaccine Development: From Preclinical Studies to Phase 1/2 Clinical Trials.

Cécile Artaud1, Leila Kara2,3,4, Odile Launay5,6,7.   

Abstract

Vaccines are biological pharmaceutical products prescribed as prevention of a hypothetical infection. Development of a new vaccine is the result of a long process involving several stages. During all developmental phases, priority is the safety of the new product, which is often used in young infants. The initial research phase lasts 1-5 years and is followed by a clinical and pharmaceutical development phase (preclinical and clinical phases), which can last from 15 to 20 years on average before licensure is obtained. There are, however, exceptions, like the malaria vaccine for which research has been going on for more than 30 years and at least 30 candidate vaccines have been assessed. This chapter summarizes the different phases of vaccine candidate development from preclinical studies to phase 2 vaccine trials.

Entities:  

Keywords:  Challenge; Clinical trial; Safety; Vaccine development

Mesh:

Substances:

Year:  2019        PMID: 31267501     DOI: 10.1007/978-1-4939-9550-9_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

Review 1.  Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.

Authors:  Jennifer H Hammel; Jonathan M Zatorski; Sophie R Cook; Rebecca R Pompano; Jennifer M Munson
Journal:  Adv Drug Deliv Rev       Date:  2022-01-11       Impact factor: 15.470

Review 2.  Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine.

Authors:  Ashwani Sharma; Tarun Virmani; Vipluv Pathak; Anjali Sharma; Kamla Pathak; Girish Kumar; Devender Pathak
Journal:  Biomed Res Int       Date:  2022-07-06       Impact factor: 3.246

Review 3.  Current situation of vaccine injury compensation program and a future perspective in light of COVID-19 and emerging viral diseases.

Authors:  Tommie Crum; Kirsten Mooney; Birendra R Tiwari
Journal:  F1000Res       Date:  2021-07-26

4.  Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies.

Authors:  Adéla Nacer; Gaily Kivi; Raini Pert; Erkki Juronen; Pavlo Holenya; Eduardo Aliprandini; Rogerio Amino; Olivier Silvie; Doris Quinkert; Yann Le Duff; Matthew Hurley; Ulf Reimer; Andres Tover; Simon J Draper; Sarah Gilbert; Mei Mei Ho; Paul W Bowyer
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.